ClinicalTrials.gg
CompletedNCT01651000Updated Jan 13, 2025Results posted

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

A Phase 3 interventional study of CTAP101 30 μg capsules and Sugar pill to CTAP101 30 μg capsules in Chronic Kidney Disease, Hyperparathyroidism, Secondary and Vitamin D Deficiency, sponsored by OPKO IP Holdings II, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by OPKO IP Holdings II, Inc. (part of OPKO Health, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
213th of 819
213 · median 72
Started
2012
with 35 others
Phase 3
147 of 988
13 open now
Registered
261st of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 213th largest by enrollment of the 819 interventional ones that give a count, is one of 36 that started in 2012, is one of 147 in phase 3, and was the 261st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated

Read the detailed description

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of CTAP101 Capsules administered for 26 weeks to treat SHPT in subjects ≥18 years of age with stage 3 or 4 CKD and vitamin D insufficiency. The study will be conducted at approximately 40 sites within the United States (US). Approximately 550 subjects will be screened to randomize approximately 210 eligible subjects, stratified by CKD stage (approximately 105 subjects in each stage) in a 2:1 ratio to receive either CTAP101 Capsules or matching placebo. An Interactive Voice Response System (IVRS) will provide study treatment group assignments using the computer-generated randomization code provided by the IVRS vendor. Subjects will receive an initial daily dose of 1 capsule (CTAP101 Capsules, 30 µg, or matching placebo) for the first 12 weeks. After l2 weeks (visit 8) and per pre-defined criteria, the dose may be increased in a blinded fashion by the IVRS with oversight by an independent medical monitor.

03

Conditions studied

  • Chronic Kidney Disease
  • Hyperparathyroidism, Secondary
  • Vitamin D Deficiency

Keywords

  • Parathyroid Diseases
  • Renal Insufficiency
  • Kidney Failure, Chronic
  • Hyperparathyroidism, Secondary
  • Vitamin D
  • Hyperparathyroidism
  • Kidney Diseases
  • Kidney Failure
  • Renal Insufficiency, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Urinary albumin excretion ≤ 3000 mcg/mg of creatinine
  2. Stage 3 or 4 CKD
  3. Plasma iPTH: ≥ 85 pg/mL and \< 500 pg/mL
  4. Serum Ca: ≥ 8.4 mg/dL and \< 9.8 mg/dL
  5. Serum P: ≥ 2.0 mg/dL and \< 5.0 mg/dL
  6. Serum 25-hydroxyvitamin D: ≥ 10 ng/mL and \< 30 ng/mL.
  7. Stable dose of Vitamin D therapy ≤ 1600 IU/day and receiving same dose for at least 2 months

Exclusion criteria

Exclusion Criteria:

  1. History of kidney transplant or parathyroidectomy
  2. Spot urine calcium:creatinine ratio > 0.2 (>200 mg/g Cr)
  3. Current serious illness, such as , , liver disease, cardiovascular event or hepatitis
  4. Currently on dialysis
  5. Use of pharmacological dose of ergocalciferol or cholecalciferol (≥ 50,000 IU mcg per month) during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
213 participants (actual)

Study arms

  • Active comparator
    CTAP101 30 μg capsules

    1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.

    Drug: CTAP101 30 μg capsules · Other: Sugar pill to CTAP101 30 μg capsules

  • Placebo comparator
    Sugar pill to CTAP101 30 μg capsule

    1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.

    Other: Sugar pill to CTAP101 30 μg capsules

Interventions

  • CTAP101 30 μg capsule taken daily at bedtime.

    Also known as: Calcifediol

  • OtherSugar pill to CTAP101 30 μg capsules

    Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values

    Number of subjects in the intent to treat population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.

    Time frame: Approximately 6 months

Secondary outcomes

  1. Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values

    Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.

    Time frame: Approximately 6 months

  2. Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D

    Subjects in the Intent to Treat Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/dL)

    Time frame: Approximately 6 months

  3. Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D

    Subjects in the Per Protocol Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/mL)

    Time frame: Approximately 6 months

07

Results

Posted Aug 17, 2016

Participant flow

This multicenter study was conducted at 44 investigational sites within the US. Subjects were enrolled and treated from 07 September 2012 through 20 July 2014.

Participant flow — Overall Study
MilestoneSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
Started72141
Entered extension study5093
Completed62113
Not completed1028
Withdrew: Adverse event28
Withdrew: Lost to follow-up32
Withdrew: Protocol violation03
Withdrew: Withdrawal by subject210
Withdrew: Subject noncompliance03
Withdrew: Lack of efficacy11
Withdrew: Physician decision10
Withdrew: Administrative reason10
Withdrew: Serum ca >/= 11.0 mg/dl, repeat confirm01

Outcome measures

PrimaryNumber of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values

Number of subjects in the intent to treat population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.

Time frame:
Approximately 6 months
Reported as:
Number · participants
Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values
participantsSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values646
Statistical analysis
  • Sugar Pill to CTAP101 30 μg Capsule vs CTAP101 30 μg Capsules · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryNumber of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values

Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.

Time frame:
Approximately 6 months
Reported as:
Number · participants
Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values
participantsSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values546
Statistical analysis
  • Sugar Pill to CTAP101 30 μg Capsule vs CTAP101 30 μg Capsules · Cochran-Mantel-Haenszel · p = <0.0001
SecondarySubjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D

Subjects in the Intent to Treat Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/dL)

Time frame:
Approximately 6 months
Reported as:
Number · participants
Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D
participantsSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D2113
Statistical analysis
  • Sugar Pill to CTAP101 30 μg Capsule vs CTAP101 30 μg Capsules · Cochran-Mantel-Haenszel · p = <0.0001
SecondarySubjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D

Subjects in the Per Protocol Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/mL)

Time frame:
Approximately 6 months
Reported as:
Number · participants
Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D
participantsSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D2110

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sugar Pill to CTAP101 30 μg Capsule—12/72 (16.7%)37/72 (51.4%)
CTAP101 30 μg Capsules—30/141 (21.3%)44/141 (31.2%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
Cardiac failure congestiveCardiac disorders0/726/141
Blood creatinine increasedInvestigations0/725/141
Chest painGeneral disorders2/722/141
AnaemiaBlood and lymphatic system disorders1/722/141
Atrial fibrillationCardiac disorders0/722/141
SepsisInfections and infestations1/722/141
UrosepsisInfections and infestations0/722/141
Renal failure acuteRenal and urinary disorders1/722/141
HyponatraemiaMetabolism and nutrition disorders1/720/141
HyperkalaemiaMetabolism and nutrition disorders1/720/141
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg Capsules
DiarrhoeaGastrointestinal disorders12/726/141
Urinary tract infectionInfections and infestations10/727/141
NauseaGastrointestinal disorders6/723/141
Back painMusculoskeletal and connective tissue disorders6/726/141
ArthralgiaMusculoskeletal and connective tissue disorders6/723/141
VomitingGastrointestinal disorders5/722/141
Oedema peripheralGeneral disorders5/723/141
HypertensionVascular disorders5/729/141
Chest painGeneral disorders4/723/141
Upper respiratory tract infectionInfections and infestations4/724/141

Baseline characteristics

Intent to Treat

Age, Continuous
Age, Continuous(years)Sugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg CapsulesTotal
Mean64.4 ± 12.7465.1 ± 10.3364.9 ± 11.18
Sex: Female, Male
Sex: Female, Male(Participants)Sugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg CapsulesTotal
Female3371104
Male3970109
Region of Enrollment
Region of Enrollment(participants)Sugar Pill to CTAP101 30 μg CapsuleCTAP101 30 μg CapsulesTotal
United States72141213
08

Study locations

1 site
  • OPKO Renal
    Bannockburn, Illinois 60015, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 1 month after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2012
First posted
Jul 26, 2012
Start
Sep 2012
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results delay requested
Oct 22, 2015
Results first posted
Aug 17, 2016
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01651000
Responsible party
Sponsor
First posted
Jul 26, 2012
Start date
Sep 2012
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Aug 17, 2016
Last update
Jan 13, 2025

Study contacts

Joel Melnick, MD
study director · Opko Renal

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion